Prevalence and risk factors of metabolic-associated fatty liver disease in sub-Saharan Africa: a systematic review and meta-analysis

Frontiers in Gastroenterology, Journal Year: 2025, Volume and Issue: 4

Published: April 1, 2025

Background Sub-Saharan Africa (SSA) is undergoing an epidemiological transition with a steady rise in non-communicable diseases. Among these diseases, metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as rapidly increasing public health burden, but inaccurately documented. We characterized the MAFLD prevalence and identified associated risk factors among adults SSA. Methods searched PubMed/Medline, Cochrane, Embase, Web of Science, Google Scholar, African Journals Online for studies looking into Studies from 1990 English language were included, Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines used reporting. The quality was assessed using Newcastle–Ottawa Scale. A random-effects model to estimate 95% confidence intervals (CIs). Meta-regression subgroup analyses account heterogeneity. Stata version 17 software analysis. This study registered PROSPERO (registration no. CRD42024506067). Results total 538 identified, 22 included overall 29·21% (95%CI = 22.09–36.88, p < 0.05). Regionally, results were: West, 34.36%; South, 26.92%; East, 24.56%. people living HIV 13.02%, diabetes 37.06%, hypertension 36.75%, body mass index above 25 kg/m 2 46.05%. higher women than men (27.13% vs . 23.01%), shown conducted 2000 onwards compared those between 2009 2019 (30.23% 28.4%) small sample sizes <500 large >500 (32.42% 12.17%). Interpretation highly prevalent SSA, magnitude. significant diabetes, hypertension, obesity, female sex. underscores emerging need clinicians SSA screen patients at high instigate tailored care. review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024506067.

Language: Английский

---

Fatty liver disease in the pediatric population: history, definitions, and challenges in nomenclature (NAFLD/MAFLD/MASLD)

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(2)

Published: April 29, 2025

This review focuses on the evolution in nomenclature of fatty liver disease pediatric population, from initial definition non-alcoholic (NAFLD) to metabolic dysfunction-associated (MAFLD), and more recently steatotic (MASLD). These changes aim accurately reflect relation between underlying alterations, while also seeking reduce stigma associated with earlier definitions. Epidemiological data indicate an increase global burden NAFLD a prevalence 5%-10%, commonly affecting males. The condition is strongly obesity, type 2 diabetes mellitus (T2DM), genetic factors, including PNPLA3 polymorphism. Prevalence rates are significantly higher Latin America (24%-68%), which linked growing epidemic syndrome. In terms pathophysiology, differs adult form histological patterns has strong link insulin resistance. Each pros cons. simple but exclusionary, MAFLD incorporates factors better characterize disease. most recent term, MASLD, aims this emphasize factor pathology. Various scientific societies consistently recommend lifestyle as first-line treatment, although adherence intervention remains challenge population. addition, there consensus need for noninvasive tools longitudinal studies understand children.

Language: Английский

---

The burden of liver disease in Latin America

Annals of Hepatology, Journal Year: 2023, Volume and Issue: 29(3), P. 101175 - 101175

Published: Nov. 3, 2023

Liver disease poses a substantial burden in Latin America. This is primarily attributed to high level of alcohol consumption and the increasing prevalence risk factors associated with metabolic dysfunction-associated steatotic liver (MASLD), such as sedentary lifestyles, easy access ultra-processed foods, obesity, type 2 diabetes mellitus. These epidemiological trends are cause for concern, especially considering that there significant challenges addressing them, due disparities screening care. In this article, we aim provide an overview current situation regarding We also discuss recent multinational proposals designed address growing MASLD via its integration into existing non-communicable diseases policies, at both local global levels. Additionally, emphasize urgent need establish effective public health policies target excessive consumption. Furthermore, development transplantation programs, areas improvement medical education research capabilities, how fostering extensive collaboration among all stakeholders crucial region.

Language: Английский

---

Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group.

Annals of Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 101903 - 101903

Published: March 1, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes chronic globally. Based on 2023 definition, MASLD characterized by presence metabolic dysfunction and limited alcohol consumption (<140 grams/week for women, <210 men). Given significant burden in Latin America, this guidance was developed American Association Study Liver (ALEH) Working Group to address key aspects its clinical assessment therapeutic strategies. In ultrasonography recommended as initial screening tool hepatic steatosis due accessibility, while Fibrosis-4 (FIB-4) preferred fibrosis risk stratification, with further evaluation using more specific techniques (i.e., vibration-controlled transient elastography or Enhanced Fibrosis [ELF] test). A Mediterranean diet advised all patients, a target 7-10% weight loss those excess weight. Complete abstinence patients fibrosis, smoking cessation encouraged regardless stage. Pharmacological options should be tailored based steatohepatitis, weight, diabetes, including resmetirom, incretin-based therapies, pioglitazone, sodium-glucose cotransporter-2 inhibitors. Bariatric surgery may considered obesity unresponsive lifestyle medical interventions. Hepatocellular carcinoma cirrhotic consideration given advanced individual risk. Finally, routine cardiovascular proper diabetes prevention management remain crucial MASLD.

Language: Английский

---

Nonalcoholic Fatty Liver Disease in Latin America and Australia

Clinics in Liver Disease, Journal Year: 2023, Volume and Issue: 27(2), P. 301 - 315

Published: Feb. 26, 2023

Language: Английский

---

The effects of pomegranate (Punica granatum) on nonalcoholic fatty liver disease: A systematic review of in vivo interventional studies

Phytotherapy Research, Journal Year: 2024, Volume and Issue: 38(8), P. 4189 - 4201

Published: June 25, 2024

Abstract Nonalcoholic fatty liver disease (NAFLD) is a disorder in which excess fat accumulates hepatocytes and can lead to serious complications. Oxidative stress one of the leading causes NAFLD. Pomegranates are considered antioxidant‐rich fruit. This systematic review study was aimed investigate impact pomegranate on PubMed, Scopus, Google Scholar databases/search engines (from inception up July 2023) were searched for interventional studies (human animal) that examined effects supplementation with different parts including fruits, peels, seeds, or flower NAFLD outcomes. A total 222 articles retrieved following initial search. After excluding duplicates, title abstract 114 screened. Afterward, irrelevant removed full texts remaining 27 reviewed. Eventually, 19 (16 animal three human studies) met inclusion criteria, published between 2009 2023, included this review. Our indicates potential beneficial improvement However, given majority studies, further investigations form clinical trials warranted suggest indication such interventions.

Language: Английский

---

Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina

Annals of Hepatology, Journal Year: 2023, Volume and Issue: 28(4), P. 101111 - 101111

Published: April 25, 2023

South America is one of the regions with highest rates non-alcoholic fatty liver disease (NAFLD). This study aimed to assess prevalence and severity NAFLD in suburban Argentina.The involved a general community cohort 993 subjects evaluated sequentially comprehensive lifestyle questionnaire, laboratory testing, abdominal ultrasound (US) transient elastography XL probe. was diagnosed according standard criteria.The by US 37.2% (326/875) overall, 50.3% overweight/obesity, 58.6% hypertriglyceridemia, 62.3% diabetes/hyperglycemia 72.1% all three risk factors. Male gender (OR 1.42, 95% CI 1.03-1.47, p = 0.029), age (50-59 years: OR 1.98, 95 1.16-3.39, 0.013 ≥60 1.86, 1.13-3.09, 0.015), BMI (25-29: 2.87, 1.86-4.51, p<0.001 ≥30: 9.57, 6.14-15.20, p<0.001), 1.65, 1.05-2.61, 0.029) hypertriglyceridemia 1.73, 1.20-2.48, 0.002) were independent predictors NAFLD. Among patients steatosis, 22.2% (69/311) had ≥F2 fibrosis (overweight 25%, 32%, 34%). 5.22, 2.64-11.74, 2.12, 1.05-4.29, 0.04) 1.94, 1.03-3.68, 0.040) fibrosis.This population from Argentina showed high Significant present 22% information adds existing knowledge epidemiology Latin America.

Language: Английский

---

Risk Factors and Prediction Models for Nonalcoholic Fatty Liver Disease Based on Random Forest

Computational and Mathematical Methods in Medicine, Journal Year: 2022, Volume and Issue: 2022, P. 1 - 7

Published: Aug. 9, 2022

Objective. To establish a risk prediction model of nonalcoholic fatty liver disease (NAFLD) and provide management strategies for preventing this disease. Methods. A total 200 inpatients physical examinees were collected from the Department Gastroenterology Endocrinology Physical Examination Center. The data examination, laboratory abdominal ultrasound examination collected. All subjects randomly divided into training set (70%) verification (30%). random forest (RF) is constructed to predict occurrence NAFLD. receiver operating characteristic (ROC) curve used verify effect models. Results. number NAFLD patients was 44 out enrolled patients, cumulative incidence rate 22%. models showed that BMI, TG, HDL-C, LDL-C, ALT, SUA, MTTP mutations independent influencing factors NAFLD, all which has statistical significance ( $P<0.05$ ). area under (AUC) logistic regression RF 0.940 (95% CI: 0.870~0.987) 0.945 0.899~0.994), respectively. Conclusion. This study established based on RF, good value.

Language: Английский

---

Metabolic dysfunction associated steatotic liver disease in resource-limited settings

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 167 - 175

Published: Feb. 15, 2024

Language: Английский

---

Curcumin nanoemulsions on the expression of fatty acid transporter proteins during hepatic steatosis

Published: Feb. 19, 2024

Introduction Fructose intake of over 70 g/day is known to cause dyslipidemias, involving multiple metabolic pathways that can promote an excess hepatic lipid synthesis as dysfunction-associated fatty liver disease (MAFLD), formerly non-alcoholic disease.

Language: Английский

---